Misonix, Inc., an ultrasonic medical devices company, announced that it had received a letter from the Securities and Exchange Commission informing the company that the SEC staff was closing its investigation with a recommendation of no enforcement action by the SEC. The company had previously reported that it had made a voluntarily disclosure to the SEC relating to possible FCPA issues caused by the business practices of the company’s distributor in China.
June 20, 2019
New York medical technology company receives declination letter from SEC in suspected foreign bribery case
Related by Topic
New Post
DOJ issues declination with disgorgement letter to Boston Consulting Group for possible FCPA offenses
August 29, 2024
News Alert
New Post
Two whistleblowers receive awards totaling to $24 million from the SEC
August 28, 2024
News Alert